Loading...
XSHE002826
Market cap264mUSD
Dec 26, Last price  
10.53CNY
1D
1.06%
1Q
23.74%
Jan 2017
-59.93%
IPO
9.69%
Name

Tibet Aim Pharm Inc

Chart & Performance

D1W1MN
XSHE:002826 chart
P/E
125.56
P/S
2.90
EPS
0.08
Div Yield, %
1.05%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
6.42%
Revenues
667m
-22.14%
221,107,828290,726,213346,995,393451,922,477380,292,645488,774,206553,255,391602,619,263725,459,075856,734,307667,038,997
Net income
15m
-65.14%
19,706,88532,372,67150,029,90455,358,45060,476,62425,255,04137,328,95041,091,16442,476,49144,135,40915,386,479
CFO
167m
+143.79%
52,240,3962,184,178057,179,40177,288,00613,313,86459,202,426101,735,689109,522,21068,453,222166,880,943
Dividend
May 31, 20240.03 CNY/sh
Earnings
May 16, 2025

Profile

Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
URL
http://www.emyy.cn/
IPO date
Dec 09, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
667,039
-22.14%
856,734
18.10%
725,459
20.38%
Cost of revenue
583,311
789,287
678,160
Unusual Expense (Income)
NOPBT
83,728
67,447
47,299
NOPBT Margin
12.55%
7.87%
6.52%
Operating Taxes
7,874
10,587
6,540
Tax Rate
9.40%
15.70%
13.83%
NOPAT
75,854
56,860
40,759
Net income
15,386
-65.14%
44,135
3.91%
42,476
3.37%
Dividends
(20,281)
(19,007)
(15,272)
Dividend yield
0.89%
0.98%
0.73%
Proceeds from repurchase of equity
(22)
(2,642)
BB yield
0.00%
0.14%
Debt
Debt current
11,011
50,051
6,648
Long-term debt
Deferred revenue
6,604
4,432
5,016
Other long-term liabilities
1,862
Net debt
(417,413)
(271,231)
(179,646)
Cash flow
Cash from operating activities
166,881
68,453
109,522
CAPEX
(3,181)
Cash from investing activities
(43,002)
Cash from financing activities
(59,303)
27,592
FCF
133,411
115,859
37,855
Balance
Cash
385,856
321,283
182,725
Long term investments
42,567
1
3,569
Excess cash
395,071
278,446
150,021
Stockholders' equity
517,398
517,316
487,529
Invested Capital
372,603
512,273
572,764
ROIC
17.14%
10.48%
7.36%
ROCE
10.91%
8.53%
6.54%
EV
Common stock shares outstanding
192,331
190,678
190,206
Price
11.87
16.49%
10.19
-6.94%
10.95
12.19%
Market cap
2,282,969
17.50%
1,943,006
-6.71%
2,082,752
12.48%
EV
1,870,598
1,676,477
1,905,827
EBITDA
107,864
90,148
71,040
EV/EBITDA
17.34
18.60
26.83
Interest
1,178
811
843
Interest/NOPBT
1.41%
1.20%
1.78%